ABSTRACT
BACKGROUND: Accumulating evidence has linked high aluminum (Al) levels with toxicity and disease. Our objective was to evaluate the Al exposure of ICU patients receiving stress ulcer prophylaxis with sucralfate and ranitidine. METHODS: Within a large prospective, randomized study, a subgroup of 30 critically ill, renally intact patients on prolonged mechanical ventilation who were being treated in intensive care units (ICU) of a university hospital were allocated to two prophylaxis subgroups: enteral sucralfate, 1 g six times daily by gastric tube (n=15), or intravenous ranitidine, 200 mg daily by 24-h continuous intravenous infusion (n=15). The Al content of large and small-volume parenterals was measured and Al intake calculated for each patient and day. Aluminum levels in serum and 24-h urine were monitored every 2 days during the 16-day observation period (days 0-15). RESULTS: Mean daily parenteral Al exposure ranged from 101.3 to 158.7 mug/day for sucralfate and ranitidine patients, respectively. In both groups, Al serum levels increased from baseline on days 1-13 and on days 3-7 in the sucralfate and ranitidine groups, respectively. From days 3-13, Al serum levels were significantly higher with sucralfate than with ranitidine (P<0.05). On days 7-13, 24-h urinary Al excretion was also significantly higher in the sucralfate than in the ranitidine group (P<0.05). CONCLUSION: In ICU patients, only approximately 50% of parenterally administered Al is eliminated renally. Sucralfate additionally increases patients exposure to Al. In ICU patients, the mean absorption of enteral Al from sucralfate is only 0.019%.
ABSTRACT
An elevated frequency of wheezing was found in school children in a rural area of Northrhine-Westphalia, Germany (Duhme and Keil, Institut für Epidemiologie und Sozialmedizin, Universität Münster, Münster, Germany 1997). In this study the prevalence of wheezing was reinvestigated by including main influencing factors. A cross-sectional survey was performed in all school children visiting school classes 1, 2 and 7, 8 (n = 1161). Two corresponding questionnaires were used: a parental questionnaire and a questionnaire for self-completion by the children aged 12-15. The latter included the ISAAC video questionnaire. The levels of immunoglobulins A, G and M were determined in 995 saliva samples. Testing of lung function (whole body plethysmography before and after physical exercise) was performed in children with and without parent-reported wheezing in the last 12 months (n = 377). Response rate (questionnaire: 93%) and participation rates (saliva samples: 86%, lung function tests: 93%) were high. Our study confirmed higher prevalence of asthmatic symptoms in children aged 6-8 in Ochtrup (13.2%) compared to children of the same age in Muenster (8.5% (Duhme et al., Eur. Respir. J. 11, 840-847, 1998)). However, in the age group 12-15 years the prevalence was significantly lower in Ochtrup (9.8%), when compared to the former investigation and in comparison to Muenster (former survey: 17.9%; Muenster: 13.1%). Prevalence of wheezing was consistently higher in families with atopic disease. Additionally, history of respiratory disease, premature birth and presence of pets during 1st year of life showed a positive association with prevalence of wheezing. Mean salivary IgA levels were 61.4 (SD (standard deviation) 35.1, median: 53.7) mg/l in children aged 6-8 years and 83.4 (SD 39.0, median: 76.3) mg/l in children aged 12-15 years. No significant association between salivary immunoglobulins and wheezing was detected.
